ABSTRACT
Oncogenic upregulation of tissue factor (TF) and release of TF-containing microvesicles play an important role in cancer-related coagulopathy (Trousseau's syndrome), angiogenesis, and disease progression. In addition, certain types of host cells (stromal cells, inflammatory cells, activated endothelium) may also express TF. Although the relative contribution of host-related versus tumor-related TF to tumor progression is not known, our recent studies indicate that the role of both sources of TF in tumor formation is complex and context-dependent. Disruption of TF expression/activity in cancer cells leads to tumor growth inhibition in immunodeficient mice, even in cases where TF overexpression is driven by potent oncogenes (K-ras or EGFR). Interestingly, TF expression in vivo appears to be influenced by many factors, including the level of oncogenic transformation, tumor microenvironment, and differentiation from cancer stem-like cells. We postulate that activation of TF signaling and coagulation may deliver growth-promoting stimuli (e.g., fibrin, thrombin, platelets) to dormant cancer stem cells (CSCs). Functionally, these influences may be tantamount to formation of a provisional (TF-dependent) cancer stem cell niche. As such, these changes may contribute to the involvement of CSCs in tumor growth, angiogenesis, and metastasis.
KEYWORDS
Tissue factor - oncogenes - cancer - angiogenesis - cancer stem cells - coagulation
REFERENCES
-
1
Folkman J.
Fundamental concepts of the angiogenic process.
Curr Mol Med.
2003;
3
643-651
-
2 Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA The Molecular Basis of Cancer. Philadelphia, PA; W.B. Saunders 1995: 206-232
-
3
Folkman J.
Angiogenesis-dependent diseases.
Semin Oncol.
2001;
28
536-542
-
4
Vlaykova T, Laurila P, Muhonen T et al..
Prognostic value of tumor vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.
Melanoma Res.
1999;
9
59-68
-
5
Bajou K, Noel A, Gerard R D et al..
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Nat Med.
1998;
4
923-928
-
6
Brooks P C, Silletti S, von Schalscha T L, Friedlander M, Cheresh D A.
Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.
Cell.
1998;
92
391-400
-
7
Wojtukiewicz M Z, Rucinska M, Zacharski L R et al..
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Thromb Haemost.
2001;
86
1416-1420
-
8
Jain R K.
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Science.
2005;
307
58-62
-
9
Hurwitz H, Fehrenbacher L, Cartwright T et al..
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC.
Proc Am Soc Clin Oncol.
2003;
21
, 22(abstract 3646)
-
10
Ferrara N.
Vascular endothelial growth factor as a target for anticancer therapy.
Oncologist.
2004;
9(Suppl 1)
2-10
-
11
Hurwitz H.
Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Clin Colorectal Cancer.
2004;
4(Suppl 2)
S62-S68
-
12
Sandler A, Gray R, Perry M C et al..
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
N Engl J Med.
2006;
355
2542-2550
-
13
Faivre S, Demetri G, Sargent W, Raymond E.
Molecular basis for sunitinib efficacy and future clinical development.
Nat Rev Drug Discov.
2007;
6
734-745
-
14
Falanga A.
Thrombophilia in cancer.
Semin Thromb Hemost.
2005;
31
104-110
-
15
Kakkar A K, Levine M N, Kadziola Z et al..
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
J Clin Oncol.
2004;
22
1944-1948
-
16
Lee A Y, Rickles F R, Julian J A et al..
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
J Clin Oncol.
2005;
23
2123-2129
-
17
Klerk C P, Smorenburg S M, Otten H M et al..
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
J Clin Oncol.
2005;
23
2130-2135
-
18
Altinbas M, Coskun H S, Er O et al..
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
J Thromb Haemost.
2004;
2
1266-1271
-
19
Belting M, Ahamed J, Ruf W.
Signaling of the tissue factor coagulation pathway in angiogenesis and cancer.
Arterioscler Thromb Vasc Biol.
2005;
25
1545-1550
-
20
Versteeg H H, Ruf W.
Emerging insights in tissue factor-dependent signaling events.
Semin Thromb Hemost.
2006;
32
24-32
-
21 Colman R W, Marder V J, Salzman E W, Hirsh J. Overview of hemostasis. In: Coleman RB, Hirsh J, Marder VJ, Salzman JB Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA; JB Lippincott 1994: 3-18
-
22
Levine M N, Lee A Y, Kakkar A K.
From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.
J Thromb Haemost.
2003;
1
1456-1463
-
23 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel Dieu de Paris. Paris, France; The Sydenham Society 2nd 1865: 654-712
-
24
Rickles F R, Patierno S, Fernandez P M.
Tissue factor, thrombin, and cancer.
Chest.
2003;
124
58S-68S
-
25
Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S.
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.
J Thromb Haemost.
2007;
5
520-527
-
26
Decousus H, Moulin N, Quenet S et al..
Thrombophilia and risk of venous thrombosis in patients with cancer.
Thromb Res.
2007;
120(Suppl 2)
S51-S61
-
27
Shirai K, Chaudhary U B.
Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer–a case report.
Scientific WorldJournal.
2007;
7
753-755
-
28
Tokar M, Bobilev D, Ariad S, Geffen D B.
Disseminated intravascular coagulation at presentation of advanced gastric cancer.
Isr Med Assoc J.
2006;
8
853-855
-
29
Petralia G A, Lemoine N R, Kakkar A K.
Mechanisms of disease: the impact of antithrombotic therapy in cancer patients.
Nat Clin Pract Oncol..
2005;
2
356-363
-
30
Rak J, Yu J L, Luyendyk J, Mackman N.
Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans.
Cancer Res.
2006;
66
10643-10646
-
31
Nierodzik M, Karpatkin S.
Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host?.
J Thromb Haemost.
2005;
3
577-580
-
32
Palumbo J S, Potter J M, Kaplan L S, Talmage K, Jackson D G, Degen J L.
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice.
Cancer Res.
2002;
62
6966-6972
-
33
Pakneshan P, Szyf M, Rabbani S A.
Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
Carcinogenesis.
2005;
26
557-564
-
34
Dano K, Behrendt N, Hoyer-Hansen G et al..
Plasminogen activation and cancer.
Thromb Haemost.
2005;
93
676-681
-
35
Folkman J.
Angiogenesis and proteins of the hemostatic system.
J Thromb Haemost.
2003;
1
1681-1682
-
36
Browder T, Folkman J, Pirie-Shepherd S.
The hemostatic system as a regulator of angiogenesis.
J Biol Chem.
2000;
275
1521-1524
-
37
Verheul H M, Pinedo H M.
Tumor growth: a putative role for platelets?.
Oncologist.
1998;
3
II
-
38
Zacharski L R, Loynes J T.
The heparins and cancer.
Curr Opin Pulm Med.
2002;
8
379-382
-
39
Rickles F R.
Mechanisms of cancer-induced thrombosis in cancer.
Pathophysiol Haemost Thromb.
2006;
35
103-110
-
40
Mackman N, Morrissey J H, Fowler B, Edgington T S.
Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade.
Biochemistry.
1989;
28
1755-1762
-
41
Chen J, Bierhaus A, Schiekofer S et al..
Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis.
Thromb Haemost.
2001;
86
334-345
-
42
Holash J, Wiegand S J, Yancopoulos G D.
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
Oncogene.
1999;
18
5356-5362
-
43
Morrissey J H.
Tissue factor: an enzyme cofactor and a true receptor.
Thromb Haemost.
2001;
86
66-74
-
44
Coughlin S R.
Protease-activated receptors in vascular biology.
Thromb Haemost.
2001;
86
298-307
-
45
Fernandez P M, Rickles F R.
Tissue factor and angiogenesis in cancer.
Curr Opin Hematol.
2002;
9
401-406
-
46
Giesen P L, Rauch U, Bohrmann B et al..
Blood-borne tissue factor: another view of thrombosis.
Proc Natl Acad Sci U S A.
1999;
96
2311-2315
-
47
Mackman N.
Tissue-specific hemostasis in mice.
Arterioscler Thromb Vasc Biol.
2005;
25
2273-2281
-
48
Rak J, Milsom C, May L, Klement P, Yu J.
Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
Semin Thromb Hemost.
2006;
32
54-70
-
49
Mueller B M, Reisfeld R A, Edgington T S, Ruf W.
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.
Proc Natl Acad Sci U S A.
1992;
89
11832-11836
-
50
Rak J, Klement G.
Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer.
Cancer Metastasis Rev.
2000;
19
93-96
-
51
Yu J L, May L, Lhotak V et al..
Oncogenic events regulating tissue factor expression.
Haematologica Reports.
2005;
1
18-20
-
52
Yu J L, May L, Klement P, Weitz J I, Rak J.
Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy.
Semin Thromb Hemost.
2004;
30
21-30
-
53
Tallman M S, Lefebvre P, Baine R M et al..
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
J Thromb Haemost.
2004;
2
1341-1350
-
54
Rong Y, Post D E, Pieper R O, Durden D L, Van Meir E G, Brat D J.
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
Cancer Res.
2005;
65
1406-1413
-
55
Del Conde I, Bharwani L D, Dietzen D J, Pendurthi U, Thiagarajan P, Lopez J A.
Microvesicle-associated tissue factor and Trousseau's syndrome.
J Thromb Haemost.
2007;
5
70-74
-
56
Sato T, Tsujino I, Ikeda D, Ieko M, Nishimura M.
Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma.
Thorax.
2006;
61
1009-1010
-
57
Milsom C, Yu J, May L et al..
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.
Thromb Res.
2007;
120(Suppl 2)
S82-S91
-
58
Nierodzik M L, Karpatkin S.
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.
Cancer Cell.
2006;
10
355-362
-
59
Ossovskaya V S, Bunnett N W.
Protease-activated receptors: contribution to physiology and disease.
Physiol Rev.
2004;
84
579-621
-
60
Pawlinski R, Pedersen B, Erlich J, Mackman N.
Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice.
Thromb Haemost.
2004;
92
444-450
-
61
Coughlin S R.
Thrombin signalling and protease-activated receptors.
Nature.
2000;
407
258-264
-
62
Leger A J, Covic L, Kuliopulos A.
Protease-activated receptors in cardiovascular diseases.
Circulation.
2006;
114
1070-1077
-
63
Kaushal V, Kohli M, Dennis R A, Siegel E R, Chiles W W, Mukunyadzi P.
Thrombin receptor expression is upregulated in prostate cancer.
Prostate.
2006;
66
273-282
-
64
Morris D R, Ding Y, Ricks T K, Gullapalli A, Wolfe B L, Trejo J.
Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.
Cancer Res.
2006;
66
307-314
-
65
Nishibori M, Mori S, Takahashi H K.
Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell.
J Pharmacol Sci.
2005;
97
25-30
-
66
Shi X, Gangadharan B, Brass L F, Ruf W, Mueller B M.
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.
Mol Cancer Res.
2004;
2
395-402
-
67
Contrino J, Hair G, Kreutzer D L, Rickles F R.
In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.
Nat Med.
1996;
2
209-215
-
68
Wojtukiewicz M Z, Sierko E, Klement P, Rak J.
The hemostatic system and angiogenesis in malignancy.
Neoplasia.
2001;
3
371-384
-
69
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T.
Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.
Br J Cancer.
2000;
83
164-170
-
70
Sawada M, Miyake S, Ohdama S et al..
Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis.
Br J Cancer.
1999;
79
472-477
-
71
Kakkar A K, Lemoine N R, Scully M F, Tebbutt S, Williamson R C.
Tissue factor expression correlates with histological grade in human pancreatic cancer.
Br J Surg.
1995;
82
1101-1104
-
72
Koomagi R, Volm M.
Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.
Int J Cancer.
1998;
79
19-22
-
73
Seto S, Onodera H, Kaido T et al..
Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis.
Cancer.
2000;
88
295-301
-
74
Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H.
Tissue factor expression and metastatic potential of colorectal cancer.
Thromb Haemost.
1998;
80
894-898
-
75
Nakasaki T, Wada H, Shigemori C et al..
Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer.
Am J Hematol.
2002;
69
247-254
-
76
Brat D J, Van Meir E G.
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.
Lab Invest.
2004;
84
397-405
-
77
Ornstein D L, Meehan K R, Zacharski L R.
The coagulation system as a target for the treatment of human gliomas.
Semin Thromb Hemost.
2002;
28
19-28
-
78
Del Conde, Shrimpton C N, Thiagarajan P, Lopez J A.
Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.
Blood.
2005;
106
1604-1611
-
79
Al Nedawi K, Szemraj J, Cierniewski C S.
Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1.
Arterioscler Thromb Vasc Biol.
2005;
25
1744-1749
-
80
Zhang Y, Deng Y, Luther T et al..
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.
J Clin Invest.
1994;
94
1320-1327
-
81
Ruf W, Mueller B M.
Tissue factor signaling.
Thromb Haemost.
1999;
82
175-182
-
82
Francis J L, Amirkhosravi A.
Effect of antihemostatic agents on experimental tumor dissemination.
Semin Thromb Hemost.
2002;
28
29-38
-
83
Ruf W, Mueller B M.
Tissue factor in cancer angiogenesis and metastasis.
Curr Opin Hematol.
1996;
3
379-384
-
84
Abe K, Shoji M, Chen J et al..
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.
Proc Natl Acad Sci U S A.
1999;
96
8663-8668
-
85
Hembrough T A, Swartz G M, Papathanassiu A et al..
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Cancer Res.
2003;
63
2997-3000
-
86
Ngo C V, Picha K, McCabe F et al..
CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.
Int J Cancer.
2007;
120
1261-1267
-
87
Toomey J R, Kratzer K E, Lasky N M, Broze Jr G J.
Effect of tissue factor deficiency on mouse and tumor development.
Proc Natl Acad Sci U S A.
1997;
94
6922-6926
-
88
Amarzguioui M, Peng Q, Wiiger M T et al..
Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells.
Clin Cancer Res.
2006;
12
4055-4061
-
89
Palumbo J S, Talmage K E, Massari J V et al..
Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.
Blood.
2007;
110
133-141
-
90
Reya T, Morrison S J, Clarke M F, Weissman I L.
Stem cells, cancer, and cancer stem cells.
Nature.
2001;
414
105-111
-
91
Rong L, Wan Y L, Liu Y C et al..
Role of tissue factor in lung metastasis of colorectal carcinoma cells in vivo [in Chinese].
Zhonghua Wei Chang Wai Ke Za Zhi..
2005;
8
447-450
-
92
Palumbo J S, Kombrinck K W, Drew A F et al..
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells.
Blood.
2000;
96
3302-3309
-
93
Palumbo J S, Degen J L.
Fibrinogen and tumor cell metastasis.
Haemostasis.
2001;
31(Suppl 1)
11-15
-
94
Langer F, Amirkhosravi A, Ingersoll S B et al..
Experimental metastasis and primary tumor growth in mice with hemophilia A.
J Thromb Haemost.
2006;
4
1056-1062
-
95
Boccaccio C, Sabatino G, Medico E et al..
The MET oncogene drives a genetic programme linking cancer to haemostasis.
Nature.
2005;
434
396-400
-
96
Milsom C, Rak J.
Regulation of tissue factor and angiogenesis-related genes by changes in cell shape.
Biochem Biophys Res Commun.
2005;
337
1267-1275
-
97
Polyak K, Hahn W C.
Roots and stems: stem cells in cancer.
Nat Med.
2006;
12
296-300
-
98
Singh S K, Hawkins C, Clarke I D et al..
Identification of human brain tumor initiating cells.
Nature.
2004;
432
396-401
-
99
Vescovi A L, Galli R, Reynolds B A.
Brain tumor stem cells.
Nat Rev Cancer.
2006;
6
425-436
-
100
Calabrese C, Poppleton H, Kocak M et al..
A perivascular niche for brain tumor stem cells.
Cancer Cell.
2007;
11
69-82
-
101
Li F, Tiede B, Massague J, Kang Y.
Beyond tumorigenesis: cancer stem cells in metastasis.
Cell Res.
2007;
17
3-14
-
102
Neuzil J, Stantic M, Zobalova R et al..
Tumor-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?.
Biochem Biophys Res Commun.
2007;
355
855-859
-
103
Rich J N.
Cancer stem cells in radiation resistance.
Cancer Res.
2007;
67
8980-8984
-
104
Bao S, Wu Q, Sathornsumetee S et al..
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
Cancer Res.
2006;
66
7843-7848
-
105
Buick R N, Pollak M N.
Perspectives on clonogenic tumor cells, stem cells, and oncogenes.
Cancer Res.
1984;
44
4909-4918
-
106
Weissman I L.
The road ended up at stem cells.
Immunol Rev.
2002;
185
159-174
-
107
Perez-Caro M, Sanchez-Garcia I.
Killing time for cancer stem cells (CSC): discovery and development of selective CSC inhibitors.
Curr Med Chem.
2006;
13
1719-1725
-
108
Sakariassen P O, Immervoll H, Chekenya M.
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies.
Neoplasia.
2007;
9
882-892
-
109
Mimeault M, Hauke R, Mehta P P, Batra S K.
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.
J Cell Mol Med.
2007;
11
981-1011
-
110
Korkaya H, Wicha M S.
Selective targeting of cancer stem cells: a new concept in cancer therapeutics.
BioDrugs.
2007;
21
299-310
-
111
Natarajan T G, FitzGerald K T.
Markers in normal and cancer stem cells.
Cancer Biomark..
2007;
3
211-231
-
112
Scadden D T.
The stem-cell niche as an entity of action.
Nature.
2006;
441
1075-1079
-
113
Li L, Neaves W B.
Normal stem cells and cancer stem cells: the niche matters.
Cancer Res.
2006;
66
4553-4557
-
114
Mizrak D, Brittan M, Alison M.
CD133: molecule of the moment.
J Pathol.
2008;
214
3-9
-
115
Huang E H, Heidt D G, Li C W, Simeone D M.
Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance.
Surgery.
2007;
141
415-419
-
116
Milsom C, Anderson G M, Weitz J I, Rak J.
Elevated tissue factor procoagulant activity in CD133-positive cancer cells.
J Thromb Haemost.
2007;
5
2550-2552
-
117
Yang Z J, Wechsler-Reya R J.
Hit 'em where they live: targeting the cancer stem cell niche.
Cancer Cell.
2007;
11
3-5
-
118
Folkins C, Man S, Xu P, Shaked Y, Hicklin D J, Kerbel R S.
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Cancer Res.
2007;
67
3560-3564
-
119
Li L, Neaves W B.
Normal stem cells and cancer stem cells: the niche matters.
Cancer Res.
2006;
66
4553-4557
-
120
Oka N, Soeda A, Inagaki A et al..
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells.
Biochem Biophys Res Commun.
2007;
360
553-559
-
121
Mechtcheriakova D, Wlachos A, Holzmuller H, Binder B R, Hofer E.
Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.
Blood.
1999;
93
3811-3823
-
122
Carmeliet P, Mackman N, Moons L et al..
Role of tissue factor in embryonic blood vessel development.
Nature.
1996;
383
73-75
-
123
Bugge T H, Xiao Q, Kombrinck K W et al..
Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation.
Proc Natl Acad Sci U S A.
1996;
93
6258-6263
-
124
Belting M, Dorrell M I, Sandgren S et al..
Regulation of angiogenesis by tissue factor cytoplasmic domain signaling.
Nat Med.
2004;
10
502-509
-
125
Viloria-Petit A, Miquerol L, Yu J L et al..
Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.
EMBO J.
2003;
22
4091-4102
-
126
Rak J, Yu J L, Kerbel R S, Coomber B L.
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?.
Cancer Res.
2002;
62
1931-1934
-
127
Yu J L, Rak J W, Coomber B L, Hicklin D J, Kerbel R S.
Effect of p53 status on tumor response to antiangiogenic therapy.
Science.
2002;
295
1526-1528
-
128
Relf M, LeJeune S, Scott P A et al..
Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Cancer Res.
1997;
57
963-969
-
129
Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G.
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Curr Pharm Des.
2007;
13
3358-3367
-
130
Shojaei F, Ferrara N.
Antiangiogenic therapy for cancer: an update.
Cancer J.
2007;
13
345-348
-
131
Yu J L, Coomber B L, Kerbel R S.
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.
Differentiation.
2002;
70
599-609
-
132
Kerbel R S, Yu J, Tran J et al..
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
Cancer Metastasis Rev.
2001;
20
79-86
-
133
Viloria-Petit A, Crombet T, Jothy S et al..
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Cancer Res.
2001;
61
5090-5101
-
134
Mackman N.
Role of tissue factor in hemostasis and thrombosis.
Blood Cells Mol Dis.
2006;
36
104-107
-
135
Versteeg H H, Schaffner F, Kerver M et al..
Inhibition of tissue factor signaling suppresses tumor growth.
Blood.
2008;
111
190-199
-
136
Forster Y, Meye A, Albrecht S et al..
Tissue specific expression and serum levels of human tissue factor in patients with urological cancer.
Cancer Lett.
2003;
193
65-73
-
137
Hamada I, Kato M, Yamasaki T et al..
Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma.
Anticancer Res.
2002;
22
4281-4284
-
138
Guan M, Su B, Lu Y.
Quantitative reverse transcription-PCR measurement of tissue factor mRNA in glioma.
Mol Biotechnol.
2002;
20
123-129
-
139
Hron G, Kollars M, Weber H et al..
Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.
Thromb Haemost.
2007;
97
119-123
-
140
Yamashita H, Kitayama J, Ishikawa M, Nagawa H.
Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype.
J Surg Oncol.
2007;
95
324-331
-
141
Nakasaki T, Wada H, Shigemori C et al..
Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer.
Am J Hematol.
2002;
69
247-254
-
142
Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H.
Tissue factor expression and metastatic potential of colorectal cancer.
Thromb Haemost.
1998;
80
894-898
-
143
Lopez-Pedrera C, Buendia P, Barbarroja N, Siendones E, Velasco F, Cuadrado M J.
Antiphospholipid-mediated thrombosis: interplay between anticardiolipin antibodies and vascular cells.
Clin Appl Thromb Hemost.
2006;
12
41-45
-
144
Rauch U, Antoniak S, Boots M et al..
Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood.
Lancet Oncol.
2005;
6
254
-
145
Sawada M, Miyake S, Ohdama S et al..
Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis.
Br J Cancer.
1999;
79
472-477
-
146
Kageshita T, Funasaka Y, Ichihashi M, Wakamatsu K, Ito S, Ono T.
Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression.
Pigment Cell Res.
2001;
14
195-200
-
147
Zhang Y, Deng Y, Luther T et al..
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.
J Clin Invest.
1994;
94
1320-1327
-
148
Uno K, Homma S, Satoh T et al..
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
Br J Cancer.
2007;
96
290-295
-
149
Han L Y, Landen Jr C N, Kamat A A et al..
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
J Clin Oncol.
2006;
24
755-761
-
150
Wang X, Wang E, Kavanagh J J, Freedman R S.
Ovarian cancer, the coagulation pathway, and inflammation.
J Transl Med.
2005;
3
25-45
-
151
Nitori N, Ino Y, Nakanishi Y et al..
Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Clin Cancer Res.
2005;
11
2531-2539
-
152
Kakkar A K, Williamson R C.
Prevention of venous thromboembolism in cancer patients.
Semin Thromb Hemost.
1999;
25
239-243
-
153
Babiker A A, Hamad O A, Sanchez J, Ronquist G, Nilsson B, Ekdahl K N.
Prothrombotic effect of prostasomes of metastatic cell and seminal origin.
Prostate.
2007;
67
378-388
-
154
Langer F, Chun F K, Amirkhosravi A et al..
Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Thromb Haemost.
2007;
97
464-470
-
155
Akashi T, Furuya Y, Ohta S, Fuse H.
Tissue factor expression and prognosis in patients with metastatic prostate cancer.
Urology.
2003;
62
1078-1082
-
156
Ohta Y, Ohta N, Tamura M et al..
Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side.
Chest.
2002;
121
1624-1627
-
157
Abdulkadir S A, Carvalhal G F, Kaleem Z et al..
Tissue factor expression and angiogenesis in human prostate carcinoma.
Hum Pathol.
2000;
31
443-447
Janusz RakM.D. Ph.D.
Montreal Children's Hospital Research Institute, 4060 Ste Catherine West, Montreal, QC
H3Z 3Z2, Canada
eMail: janusz.rak@mcgill.ca
